Cancer Treatment Reviews
Volume 27, Issue 4 , Pages 221-233 , August 2001

Drug interactions with the taxanes: clinical implications

References 

    REFERENCES
  1. Baker SD. Drug interactions with the taxanes. Pharmacotherapy. 1997;17:126S–132S
  2. Dorr RT. Pharmacology of the taxanes. Pharmacotherapy. 1997;17:96S–104S
  3. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 1998;55:5–30
  4. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 1996;56:1851–1854
  5. Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology. 1999;54:22–29
  6. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 1994;54:5543–5546
  7. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 1996;56:58–65
  8. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics. 1998;8:391–401
  9. Kearns CM. Pharmacokinetics of the taxanes. Pharmacotherapy. 1997;17:105S–109S
  10. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996;56:2112–2115
  11. Ellis AG, Webster LK. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. Cancer Chemother Pharmacol. 1999;43:13–18
  12. Jamis-Dow CA, Klecker RW, Katki AG, Collins JM. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol. 1995;36:107–114
  13. Rowinsky EK, Gilbert MR, McGuire WP. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991;9:1692–1703
  14. LeBlanc GA, Sundseth SS, Weber GF, Waxman DJ. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res. 1992;52:540–547
  15. Efferth T, Fabry U, Osieka R. Damage of the kinesin heavy chain gene contributes to the antagonism of cisplatin and paclitaxel. Anticancer Res. 2000;20:3211–3219
  16. Gudkov AV, Kazarov AR, Thimmapaya R, Axenovich SA, Mazo IA, Roninson IB. Cloning mammalian genes by expression selection of genetic suppressor elements: association of kinesin with drug resistance cell immortalization. Proc Natl Acad Sci. 1994;91:3744–3748
  17. Pronk LC, Schellens JH, Planting AS. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol. 1997;15:1071–1079
  18. Sparano JA. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies. Semin Oncol. 1998;25:10–15
  19. Sparano JA. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Semin Oncol. 1998;25(4 Suppl 10):66–71
  20. Holmes FA, Madden T, Newman RA. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paciltaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996;14:2713–2721
  21. Gianni L, Vigano L, Locatelli A. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997;15:1906–1915
  22. Gianni L, Munzone E, Capri G. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study [see comments]. J Clin Oncol. 1995;13:2688–2699
  23. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Int Med. 1982;6:133–139
  24. Berg SL, Cowan KH, Balis FM. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst. 1994;86:143–145
  25. Fisherman JS, Cowan KH, Noone M. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol. 1996;14:774–782
  26. Reichman BS, Seidman AD, Crown JP. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1993;11:1943–1951
  27. Holmes FA, Walters RS, Theriault RL. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83:1797–1805
  28. Sparano JA, Speyer J, Gradishar WJ. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. J Clin Oncol. 1999;17:880–886
  29. Esposito M, Venturini M, Vannozzi MO. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J Clin Oncol. 1999;17:1132
  30. Venturini M, Lunardi G, Del Mastro L, Vannozzi MO, Tolino G, Numico G, et al. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Onc. 2000;18:2116–2125
  31. Fetell MR, Grossman SA, Fisher JD. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol. 1997;15:3121–3128
  32. Chang SM, Kuhn JG, Rizzo J. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol. 1998;16:2188–2194
  33. Relling MVC-HP, Sandlund JT, Rivera GK, Hancock ML, Booyett JM, Schuetz EG, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. The Lancet. 2000;356:285–290
  34. van Warmerdam LJ, Huizing MT, Giaccone G. Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol. 1997;24:S2–97–S2–104
  35. Belani CP, Kearns CM, Zuhowski EG. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17:676–684
  36. Bookman MA, McGuire WP, Kilpatrick D. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol. 1996;14:1895–1902
  37. Huizing MT, Giaccone G, van Warmerdam LJ. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol. 1997;15:317–329
  38. Obasaju CK, Johnson SW, Rogatko A. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res. 1996;2:549–552
  39. Kearns CM, Belani CP, Erkmen K. Pharmacokinetics of paclitaxel and carboplatin in combination. Semin Oncol. 1995;22:1–4; discussion 5–7
  40. Calvert AH, Boddy A, Bailey NP. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions [published erratum appears in Semin Oncol 1996 Dec; 23: 781]. Semin Oncol. 1995;22:91–98; discussion 9–100
  41. Vaughn D, Mick R, Ratajczak J. Investigating the platelet sparing mechanism of paclitaxel/carboplatin chemotherapy. Proc Am Soc Clin Oncol. 1997;16:253a
  42. Mulatero C, McClaren BR, Mason M, Oliver RT, Gallagher CJ. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma. Brit J Can. 2000;83:1612–1616
  43. Budman DR, Calabro A, Wang LG, Liu XM, Stiel L, Adams LM, et al. Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Can Invest. 2000;18:804–805
  44. Taylor CW, Wang LM, List AF. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer. 1997;33:1693–1698
  45. DiPaolo R, Rodriguez R, Recio A, Goodin S, Orlick M, Mollman J, et al. A phase I study of amifostine and paclitaxel in patients with advanced malignancies.. 1996; p. 488
  46. Schuller J CA, Pietrzak C, Springer B, Wirth M, Schernthaner G. Influence of the cytoprotective agent amifostine (AMI) on pharmacokinetics (PK) of paclitaxel (PAC) and Taxotere (TXT). Proc Am Soc Clin Oncol. 1997;16:224a.
  47. Gelmon K, Eisenhauer E, Bryce C. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol. 1999;17:3038–3047
  48. Kennedy MJ, Zahurak ML, Donehower RC. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol. 1996;14:783–791
  49. Tolcher AW, Cowan KH, Noone MH. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol. 1996;14:95–102
  50. Schrijvers D, Pronk L, Highley M, Bruno R, Locci-Tonelli D, De Bruijn E, et al. Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. Am J Clin Onc. 2000;23:358–363
  51. Zeng S, Chen YZ, Fu L, Johnson KR, Fan W. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells. Clin Can Res. 2000;6:3766–3773
  52. D’Incalci M, Schuller J, Colombo T, Zucchetti M, Riva A. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin Oncol. 1998;25:16–20
  53. Aebi S, Schnider TW, Los G. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother Pharmacol. 1999;44:259–265
  54. Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE. A phase I/II trial of paclitaxel for non-Hodgkin’s lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anticancer Drugs. 1998;9:135–140
  55. Tolcher AW, Cowan KH, Solomon D, Berg S, Venzon D, Goldspiel B, et al. A phase I study of pacltaxel (T) with R-verapamil (RV) in metastatic breast cancer (MBC),. 1994; p. A349
  56. Berg SL, Tolcher A, O’Shaughnessy JA. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol. 1995;;13:2039–2042
  57. O’Reilly S, Fleming GF, Barker SD. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15:177–186
  58. Miller AA, Lilenbaum RC, Lynch TJ. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel [letter]. J Clin Oncol. 1996;14:1964–1965
  59. Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res. 1993;;53:2066–2070
  60. Hahn SM, Liebmann JE, Cook J. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer. 1993;72:2705–2711
  61. Budman DR, Calabro A, Kreis W. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anticancer Drugs. 1998;9:697–702
  62. Perez EA, Buckwalter CA. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines. Cancer Chemother Pharmacol. 1998;41:448–452
  63. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 1997;57:3375–3380
  64. Kano Y, Akutsu M, Tsunoda S, Mori K, Suzuki K, Adachi KI. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother Pharmacol. 1998;42:91–98
  65. Grem JL, Nguyen D, Monahan BP, Kao V, Geoffroy FJ. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol. 1999;58:477–486
  66. Kano Y, Akutsu M, Tsunoda S. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer. 1996;74:704–710
  67. Petit T, Aylesworth C, Burris H. A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies. Ann Oncol. 1999;10:223–229
  68. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol. 1999;22:580–586
  69. Herceptin Package Insert, Genentech Inc. South San Francisco, CA, 1998
  70. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts [published erratum appears in Cancer Res 1999 Apr 15; 59(8):2020]. Cancer Res. 1998;58:2825–2831
  71. Pegram M, Hsu S, Lewis G. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18:2241–2251
  72. Racker E, Wu LT, Westcott D. Use of slow Ca2+ channel blockers to enhance inhibition by taxol of growth of drug-sensitive and -resistant Chinese hamster ovary cells. Cancer Treat Rep. 1986;70:275–278
  73. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999;83:263–269
  74. Waltimire CN, Raymond MA, Dorr RT. Combination chemotherapy using paclitaxel carboplatin and bleomycin in human lung cancer cells. Proc Amer Assoc Cancer Res. 2000;41:143
  75. Rorer Rhone-Poulene Taxotere (docetaxel) package insert. Collegeville, PA, 1999
  76. Anderson CD, Wang J, Kumar GN, McMillan JM, Walle UK, Walle T. Dexamethasone induction of taxol metabolism in the rat. Drug Metab Dispos. 1995;23:1286–1290
  77. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Therap. 2000;68:356–366
  78. Jamis-Dow CA, Pearl ML, Watkins PB, Blake DS, Klecker RW, Collins JM. Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole. Am J Clin Oncol. 1997;20:592–599
  79. Shi B, Yaremko B, Hajian G, Terracina G, Bishop WR, Liu M, et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Can Chemother Pharmacol. 2000;46:387–393
  80. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St John’s Wort: effect on CYP3A4 activity. Clin Pharmacol Ther. 2000;67:451–457

PII: S0305-7372(01)90228-2

doi: 10.1053/ctrv.2001.0228

Cancer Treatment Reviews
Volume 27, Issue 4 , Pages 221-233 , August 2001

Article Tools